{"id":7467,"date":"2018-06-28T13:42:47","date_gmt":"2018-06-28T13:42:47","guid":{"rendered":"https:\/\/website.prod.unilu.spikeseed.cloud\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/"},"modified":"2018-06-28T13:42:47","modified_gmt":"2018-06-28T13:42:47","slug":"the-lcsb-and-ksilink-are-exploring-new-territory-together","status":"publish","type":"news","link":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/","title":{"rendered":"The LCSB and Ksilink are exploring new territory together"},"content":{"rendered":"

Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.<\/p>

Around seven million people in the world suffer from Parkinson\u2019s disease, and the number is rising. Although medical professionals are already quite capable of treating the symptoms of the disease, in which brain cells die off, there is still no therapy that eliminates the causes of the disease.<\/p>

The LCSB and the Strasbourg-based, private-public technology company Ksilink are now working together to tackle this problem. Together, they want to develop novel, patient-based cell culture models in which they can automatically and with artificial intelligence (AI) test drug candidates from a large substance library<\/strong>.<\/p>

\n \n\"\"\n

\n Les \u00e9quipes du LCSB et de Ksilink, d’en haut \u00e0 gauche: Javier Jarazo, Ibrahim Boussaad, Philippe Lucarelli, Mona Boye, Peter Sommer, Antoine De Lacombe, Rejko Kr\u00fcger, Anke Vogler, St\u00e9phane Pallage, Ulf Nehrbass & Peter Barbuti. <\/p>\n <\/figure>

<\/p>

With a runtime of five years and an investment volume of more than eight million euros, the project is an important public-private partnership. Part of its budget is funded through the BRIDGES programme of the National Research Fund (FNR). \u201cThis underscores the potential that Ksilink sees in our clinical research expertise,\u201d says Prof. Rejko Kr\u00fcger<\/a>, head of the Clinical & Experimental Neuroscience Group<\/a> at the LCSB. Ksilink\u2019s business developer, Dr Mona Boye, agrees: \u201cCombining the LCSB\u2019s patient-based cell cultures and clinical competence with our expertise in phenotypic drug discovery and industrial drug development presents a chance to make a real breakthrough in the development of therapies for Parkinson\u2019s disease.\u201d<\/p>

Parkinson\u2019s disease has many causes. Of the potential triggers, one that stands out is genetic mutations. Researchers from the LCSB and Ksilink are therefore focusing on such mutations, as Rejko Kr\u00fcger explains: \u201cOur patient cohort in the National Centre for Parkinson\u2019s Disease \u2013 NCER-PD \u2013 gives us access at the LCSB to tissue samples from Parkinson\u2019s patients and from healthy volunteers in the study. Thanks to novel laboratory methods for high-throughput analysis of patient cell cultures using robotics, which we have developed over recent years with financial backing from the FNR, we can now do studies on these samples that could give us very specific pointers to potential drugs that will treat Parkinson\u2019s disease<\/strong>.\u201d<\/p>\n

\nDeveloping drugs to treat Parkinson\u2019s disease<\/h2>\n

To do this, the researchers first convert the cells from tissue samples into so-called pluripotent stem cells in the laboratory<\/strong>. From these, they can then obtain precisely the type of cell that is most affected by Parkinson\u2019s disease, namely dopaminergic nerve cells, and therefore of greatest importance in this context. Dopaminergic nerve cells exhibit very specific mutations in their DNA. \u201cIn recent years, in cooperation with the Developmental & Cellular Biology Group<\/a> of Prof. Jens Schwamborn<\/a>, we have built up the special expertise required for developing such specific Parkinson cell models at the LCSB,\u201d Kr\u00fcger says.<\/p>

The patients\u2019 cell cultures are then examined in large numbers under the high-resolution microscopes of Ksilink. Serving as controls are cell cultures from healthy relatives or from rescue models \u2013 cell cultures in which the mutation has been repaired using the latest in gene editing techniques, for example CRISPR-Cas, the so-called \u201cmolecular scissors\u201d. \u201cWe have imaging techniques to analyse cell cultures automatically, including the use of self-learning algorithms, or in other words artificial intelligence,\u201d says Mona Boye. \u201cThe use of AI enables us to detect even very subtle and heterogeneous structural changes in the cells when comparing them with the control cells. Only fully automated high-throughput technology like that at Ksilink allows us to test big substance libraries and achieve meaningful results.<\/strong>\u201d<\/p>

Under Ksilink\u2019s high-resolution microscopes, molecules from the substance library are introduced into cell cultures originating from patients and with typical Parkinson\u2019s changes, and into genetically engineered controls that do not develop Parkinson’s disease. \u201cIn these cell cultures, we will then use our image analysis techniques to observe which substances are able to push the diseased cells towards a healthy state<\/strong>,\u201d Boye says. \u201cThis way, we can identify potential drug candidates which we will examine more closely and then develop further into preclinically validated candidates.\u201d<\/p>\n

\nCombining technologies to advance Parkinson\u2019s research<\/h2>\n

Another step will be to clarify the mechanism of action.<\/strong> \u201cOur approach is described as undirected,\u201d Boye explains. \u201cWe don\u2019t focus on a specific target molecule or specific signal transduction path; rather we test the substances in the complete, complex cell system. There is a strong chance of identifying a novel active substance that represents a completely new class of active substances. The exact target molecule and mechanism of action will then be determined as a part of downstream drug development.\u201d If these investigations are successful, i.e. if a substance exhibits the desired effect in the cell system and a tolerable mechanism of action can be demonstrated, then the potential active substance will go into subsequent preclinical and clinical development. \u201cThe likelihood that this innovative approach for identifying new active substances will result in a drug is much higher than with classical approaches,\u201d Boye explains. \u201cIn our collaboration with the LCSB, we use patient-based cell models right from the start. Potential active substances are identified directly with the help of these patient cells and expedited into preclinically validated candidates under consideration of industrial standards. Technical or regulatory errors, which could otherwise occur in the lab in the early phase without close industrial connections, are thus avoided.\u201d<\/p>

For Rejko Kr\u00fcger, the collaboration between Ksilink and the LCSB is a high point in the four years he has been working in Luxembourg. \u201cThanks to the PEARL Grant from the FNR and the Luxembourg Parkinson\u2019s study (NCER-PD) \u2013 which we were able to establish with strong support from Luxembourg \u2013 and given the ideal research conditions in the Grand Duchy, we have been able to acquire a scientific excellence that has made our research groups at the LCSB and our many clinical-scientific partners in the country highly attractive for cooperation with pharmaceutical companies. If the collaboration with Ksilink now truly culminates in a promising drug candidate that does pass the subsequent clinical trials, this would definitely represent a highlight in our joint Parkinson\u2019s research in Luxembourg.\u201d<\/p>\n

\n\u00a9 University of Luxembourg<\/h5>\n<\/div><\/section>","protected":false},"excerpt":{"rendered":"

Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.<\/p>\n","protected":false},"author":0,"featured_media":7468,"template":"","format":"standard","meta":{"featured_image_focal_point":[],"show_featured_caption":false,"ulux_newsletter_groups":"","uluxPostTitle":"","uluxPrePostTitle":"","_trash_the_other_posts":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false},"news-category":[10],"news-topic":[26],"organisation":[209,233],"authorship":[],"acf":[],"yoast_head":"\nThe LCSB and Ksilink are exploring new territory together - University of Luxembourg<\/title>\n<meta name=\"description\" content=\"Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The LCSB and Ksilink are exploring new territory together\" \/>\n<meta property=\"og:description\" content=\"Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\" \/>\n<meta property=\"og:site_name\" content=\"UNI EN\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/uni.lu\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"The LCSB and Ksilink are exploring new territory together\",\"datePublished\":\"2018-06-28T13:42:47+00:00\",\"dateModified\":\"2018-06-28T13:42:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\"},\"wordCount\":1028,\"publisher\":{\"@id\":\"https:\/\/www.uni.lu\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg\",\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\",\"url\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\",\"name\":\"The LCSB and Ksilink are exploring new territory together - University of Luxembourg\",\"isPartOf\":{\"@id\":\"https:\/\/www.uni.lu\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg\",\"datePublished\":\"2018-06-28T13:42:47+00:00\",\"dateModified\":\"2018-06-28T13:42:47+00:00\",\"description\":\"Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage\",\"url\":\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg\",\"contentUrl\":\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg\",\"width\":800,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.uni.lu\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.uni.lu\/en\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The LCSB and Ksilink are exploring new territory together\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.uni.lu\/en\/#website\",\"url\":\"https:\/\/www.uni.lu\/en\/\",\"name\":\"Uni.lu\",\"description\":\"University of Luxembourg\",\"publisher\":{\"@id\":\"https:\/\/www.uni.lu\/en\/#organization\"},\"alternateName\":\"University of Luxembourg\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.uni.lu\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.uni.lu\/en\/#organization\",\"name\":\"University of Luxembourg\",\"alternateName\":\"Uni.lu\",\"url\":\"https:\/\/www.uni.lu\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.uni.lu\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2026\/03\/03120157\/UNIV_SM-Profile_1600x1600px-scaled.jpg\",\"contentUrl\":\"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2026\/03\/03120157\/UNIV_SM-Profile_1600x1600px-scaled.jpg\",\"width\":2560,\"height\":2560,\"caption\":\"University of Luxembourg\"},\"image\":{\"@id\":\"https:\/\/www.uni.lu\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/uni.lu\",\"https:\/\/www.linkedin.com\/school\/university-of-luxembourg\/\",\"https:\/\/www.instagram.com\/uni.lu\",\"https:\/\/www.youtube.com\/@uni_lu\",\"https:\/\/en.wikipedia.org\/wiki\/University_of_Luxembourg\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The LCSB and Ksilink are exploring new territory together - University of Luxembourg","description":"Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/","og_locale":"en_GB","og_type":"article","og_title":"The LCSB and Ksilink are exploring new territory together","og_description":"Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.","og_url":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/","og_site_name":"UNI EN","article_publisher":"https:\/\/www.facebook.com\/uni.lu","og_image":[{"width":800,"height":600,"url":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#article","isPartOf":{"@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/"},"author":{"name":"","@id":""},"headline":"The LCSB and Ksilink are exploring new territory together","datePublished":"2018-06-28T13:42:47+00:00","dateModified":"2018-06-28T13:42:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/"},"wordCount":1028,"publisher":{"@id":"https:\/\/www.uni.lu\/en\/#organization"},"image":{"@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage"},"thumbnailUrl":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg","inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/","url":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/","name":"The LCSB and Ksilink are exploring new territory together - University of Luxembourg","isPartOf":{"@id":"https:\/\/www.uni.lu\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage"},"image":{"@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage"},"thumbnailUrl":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg","datePublished":"2018-06-28T13:42:47+00:00","dateModified":"2018-06-28T13:42:47+00:00","description":"Representatives of the University of Luxembourg and the technology company Ksilink which is developing novel patient-based forms of therapy, signed a collaboration agreement last Friday. The agreement constitutes the framework for collaboration between Ksilink and the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg for developing drugs to treat Parkinson\u2019s disease.","breadcrumb":{"@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#primaryimage","url":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg","contentUrl":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2018\/06\/le_lcsb_et_ksilink_innovent_ensemble.jpg","width":800,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/www.uni.lu\/en\/news\/the-lcsb-and-ksilink-are-exploring-new-territory-together\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.uni.lu\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.uni.lu\/en\/news\/"},{"@type":"ListItem","position":3,"name":"The LCSB and Ksilink are exploring new territory together"}]},{"@type":"WebSite","@id":"https:\/\/www.uni.lu\/en\/#website","url":"https:\/\/www.uni.lu\/en\/","name":"Uni.lu","description":"University of Luxembourg","publisher":{"@id":"https:\/\/www.uni.lu\/en\/#organization"},"alternateName":"University of Luxembourg","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.uni.lu\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.uni.lu\/en\/#organization","name":"University of Luxembourg","alternateName":"Uni.lu","url":"https:\/\/www.uni.lu\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.uni.lu\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2026\/03\/03120157\/UNIV_SM-Profile_1600x1600px-scaled.jpg","contentUrl":"https:\/\/www.uni.lu\/wp-content\/uploads\/sites\/9\/2026\/03\/03120157\/UNIV_SM-Profile_1600x1600px-scaled.jpg","width":2560,"height":2560,"caption":"University of Luxembourg"},"image":{"@id":"https:\/\/www.uni.lu\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/uni.lu","https:\/\/www.linkedin.com\/school\/university-of-luxembourg\/","https:\/\/www.instagram.com\/uni.lu","https:\/\/www.youtube.com\/@uni_lu","https:\/\/en.wikipedia.org\/wiki\/University_of_Luxembourg"]}]}},"blog_id":9,"_links":{"self":[{"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/news\/7467"}],"collection":[{"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/types\/news"}],"version-history":[{"count":0,"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/news\/7467\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/media\/7468"}],"wp:attachment":[{"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/media?parent=7467"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/news-category?post=7467"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/news-topic?post=7467"},{"taxonomy":"organisation","embeddable":true,"href":"https:\/\/www.uni.lu\/en\/wp-json\/wp\/v2\/organisation?post=7467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}